Accretion Pharmaceuticals IPO
smelistedAbout the company
Incorporated in 2012, Accretion Pharmaceuticals is engaged in the business of manufacturing and marketing tablets, capsules, oral liquids, and external preparations (Ointment, Cream, Gel, Lotion & more). The company operates on a B2B model, serving domestic and export clients through direct sales and contract manufacturing. It earned 72.9% of its total revenue from the top 10 clients in FY24. The company has a manufacturing facility in Sanand, which has advanced machinery and efficient processes tailored to customer demand.
Strengths
Risks
Financial performance (₹ Cr)
Subscription breakup (final, times)
IPO Roadmap / Timeline
IPO Opens
Completed14 May 2025Bidding starts for all investor categories
IPO Closes
Completed16 May 2025Last day to place your bid
Basis of Allotment
Completed19 May 2025Share allotment finalised
Refund Initiation
Completed20 May 2025Refunds credited for non-allottees
Credit to Demat
Completed20 May 2025Allotted shares credited to demat account
Listing on Exchange
Completed21 May 2025Shares list on NSE / BSE
Post-close dates are indicative as per SEBI T+3 listing framework and may change per registrar updates.
Lot size & minimum investment
| Investor Type | Min Lots | Min Shares | Min Amount | Max Lots | Max Amount | Notes |
|---|---|---|---|---|---|---|
| Retail / Individual | 1 | 1200 | ₹121,200 | 1 | ₹121,200 | 1 lot only |
| HNI | 2 | 2400 | ₹242,400 | 2 | ₹242,400 | Min 2 lots |
Shares reserved per category & allotment probability
| Category | Reservation | Shares Offered | Amount (₹ Cr) | Shares Bid | Subscribed | Allotment % |
|---|---|---|---|---|---|---|
| QIB | 50% | 1,472,081 | 14.5 | 0 | 0.00x | 100% |
| NII | 15% | 441,624 | 4.35 | 0 | 0.00x | 100% |
| Retail | 35% | 1,030,457 | 10.15 | 0 | 0.00x | 100% |
Retail is a lottery-based allotment when oversubscribed; QIB/NII get pro-rata. Probability ≈ 1 / subscription times (100% if under-subscribed).
